UK's NICE OKs BMS' Opdivo-Yervoy Combo In Advanced Skin Cancer
Executive Summary
The UK HTA has recommended Bristol-Myers Squibb's combination therapy of Opdivo and Yervoy to treat patients on the publicly-funded NHS with advanced skin cancer, marking one of the quickest decisions ever from NICE and issued only weeks after the combo was licensed by the EU's European Commission.